These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 2832298)
1. Effects of corticotropin releasing hormone on human brain function: an analysis based on auditory evoked potentials. Fehm HL; Born J Horm Metab Res Suppl; 1987; 16():75-9. PubMed ID: 2832298 [TBL] [Abstract][Full Text] [Related]
2. Changes in late auditory evoked potentials induced by corticotropin-releasing hormone and corticotropin fragment 4-9 in male controls. Hartmann A; Krumrey K; Vogl L; Dirlich G; Holsboer F; Heuser-Link M Neuropsychobiology; 1996; 33(2):90-6. PubMed ID: 8927235 [TBL] [Abstract][Full Text] [Related]
3. Influences of peripheral adrenocorticotropin 1-39 (ACTH) and human corticotropin releasing hormone (h-CRH) on human auditory evoked potentials (AEP). Born J; Bathelt B; Pietrowsky R; Pauschinger P; Fehm HL Psychopharmacology (Berl); 1990; 101(1):34-8. PubMed ID: 2160665 [TBL] [Abstract][Full Text] [Related]
4. Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10. Born J; Bräuninger W; Fehm-Wolfsdorf G; Voigt KH; Pauschinger P; Fehm HL Exp Brain Res; 1987; 67(1):85-92. PubMed ID: 3040455 [TBL] [Abstract][Full Text] [Related]
5. Brain evoked responses, a bioassay for central actions of adrenocorticotropin (ACTH 1-39) and corticotropin releasing hormone (CRH) in humans. Born J; Seidel E; Pietrowsky R; Fehm HL Horm Metab Res; 1991 Mar; 23(3):126-30. PubMed ID: 1650750 [TBL] [Abstract][Full Text] [Related]
6. An ACTH 4-9 analog impairs selective attention in man. Born J; Fehm-Wolfsdorf G; Schiebe M; Birbaumer N; Fehm HL; Voigt KH Life Sci; 1985 Jun; 36(22):2117-25. PubMed ID: 2987636 [TBL] [Abstract][Full Text] [Related]
7. Influences of ACTH 4-10 on event-related potentials reflecting attention in man. Born J; Fehm-Wolfsdorf G; Voigt KH; Fehm HL Physiol Behav; 1987; 39(1):83-7. PubMed ID: 3031714 [TBL] [Abstract][Full Text] [Related]
8. ACTH and attention in humans: a review. Born J; Fehm HL; Voigt KH Neuropsychobiology; 1986; 15(3-4):165-86. PubMed ID: 3024062 [TBL] [Abstract][Full Text] [Related]
9. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314 [TBL] [Abstract][Full Text] [Related]
10. Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: a comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP. Watanobe H; Tamura T J Clin Endocrinol Metab; 1994 Jun; 78(6):1372-7. PubMed ID: 8200939 [TBL] [Abstract][Full Text] [Related]
11. Pituitary proopiomelanocortin-derived peptides and hypothalamus-pituitary-interrenal axis activity in gilthead sea bream (Sparus aurata) during prolonged crowding stress: differential regulation of adrenocorticotropin hormone and alpha-melanocyte-stimulating hormone release by corticotropin-releasing hormone and thyrotropin-releasing hormone. Rotllant J; Balm PH; Ruane NM; Pérez-Sánchez J; Wendelaar-Bonga SE; Tort L Gen Comp Endocrinol; 2000 Aug; 119(2):152-63. PubMed ID: 10936035 [TBL] [Abstract][Full Text] [Related]
12. Brain potentials and attention after acute and subchronic intranasal administration ofACTH 4-10 and desacetyl-alpha-MSH in humans. Smolnik R; Mölle M; Fehm HL; Born J Neuroendocrinology; 1999 Jul; 70(1):63-72. PubMed ID: 10420094 [TBL] [Abstract][Full Text] [Related]
13. Vasopressin and electrophysiological signs of attention in man. Born J; Fehm-Wolfsdorf G; Lutzenberger W; Voigt KH; Fehm HL Peptides; 1986; 7(2):189-93. PubMed ID: 3737444 [TBL] [Abstract][Full Text] [Related]
14. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV J Clin Endocrinol Metab; 1994 Jul; 79(1):140-4. PubMed ID: 8027217 [TBL] [Abstract][Full Text] [Related]
15. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Broadbear JH; Winger G; Rivier JE; Rice KC; Woods JH Neuropsychopharmacology; 2004 Jun; 29(6):1112-21. PubMed ID: 14997174 [TBL] [Abstract][Full Text] [Related]
16. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. Lamberts SW; Verleun T; Oosterom R; de Jong F; Hackeng WH J Clin Endocrinol Metab; 1984 Feb; 58(2):298-303. PubMed ID: 6319446 [TBL] [Abstract][Full Text] [Related]
17. Effects of repetitive administration of recombinant human interleukin-1 beta, an analog or corticotropin-releasing hormone combined with lysine vasopressin on rats with glucocorticoid-induced secondary adrenocortical insufficiency. Murakami N; Fukata J; Usui T; Naito Y; Tominaga T; Nakai Y; Masui Y; Nakao K; Imura H J Pharmacol Exp Ther; 1992 Mar; 260(3):1344-8. PubMed ID: 1312168 [TBL] [Abstract][Full Text] [Related]
18. The relationship of saline-induced changes in vasopressin secretion to basal and corticotropin-releasing hormone-stimulated adrenocorticotropin and cortisol secretion in man. Rittmaster RS; Cutler GB; Gold PW; Brandon DD; Tomai T; Loriaux DL; Chrousos GP J Clin Endocrinol Metab; 1987 Feb; 64(2):371-6. PubMed ID: 3025246 [TBL] [Abstract][Full Text] [Related]
19. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency. Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283 [TBL] [Abstract][Full Text] [Related]
20. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]